High-relaxivity and High-stability Supramolecular MRI Contrast Agent Based on Modified β-Cyclodextrin / Gadolinium Complexes

International audienc

Synthesis, Thermodynamic And Relaxitivy Properties Of Novel β-Cyclodextrins Bicarboxylates Mri Probe.

International audienc

Polyaminocarboxylate based on b-cyclodextrin scaffold: new contrast agents for MRI

International audienc

Synthesis, thermodynamic and relaxivity properties of novel -cyclodextrins bicarboxylates MRI probe

International audienc

Synthèse et caractérisation d’agents de contraste pour IRM à base de complexes β-cyclodextrine modifiée et de Gadolinium

International audienc

Development of new contrast agents for MRI based on -cyclodextrin regiofunctionnalized by innovative gadolinium ligands

International audienc

Caractérisation physico-chimique de nouveaux agents de contraste à base de cyclodextrines modifiées par des fonctions carboxyliques

International audienc

New Ferromagnetic Nanoparticles for Water Remediation

International audienc

Development of cyclodextrin microspheres for pulmonary drug delivery

International audiencePurpose. Microparticles of diameter < 5 μm were synthesized by interfacial cross-linking of 7.5% (w/v) β-cyclodextrins (β-CD) with 4.5% (w/v) terephtaloyle chloride in 1 M NaOH, in order to provide stable vector for drug encapsulation suitable for administration at the alveolar scale.Methods. Batches were prepared varying different parameters such as amount of monomer (β-CD) (5-30% w/v), NaOH concentration (0.5-4 M), reaction time (15-240 min), agitation rate (8000-24000 rpm), amount of cross-linking agent (terephtaloyle chloride: 1.25-10% w/v), surfactant percentage (2.5-10% of Span 85), studying the influence of the freeze-drying step. Microparticles were controlled with respect to their size by a laser diffraction technique, pH of the colloidal suspension, IR spectroscopy, Differential Scanning Calorimetry. After optimization of the microparticles size, complexation with amikacin sulfate was investigated comparing encapsulation efficiency and yield at each step of the preparation (solubilization, emulsification, cross-linking, freeze-drying), contact time and influence of the amount of amikacin.Results. An optimized method was obtained with 1 M NaOH, 4.5% (w/v) cross-linking agent and 5% (w/v) surfactant agent, a 30 min reaction time, a 24000 rpm agitation rate, conducting to microparticles whose size is inferior to 5 μm. Amikacin sulfate encapsulation in polycondensed β-cyclodextrin showed that better incorporation was obtained during the solubilization step or just before freeze-drying.Conclusions. Amikacin encapsulation in 5 μm diameter microparticles of β-CD is achievable for pulmonary drug delivery

Solubility and Dissolution Rate of Progesterone-Cyclodextrin-Polymer Systems

International audienc